Pegram Excited for Additional Advances in HER2+ Breast Cancer
Mark Pegram, MD Though some clinicians may characterize the treatment landscape of HER2-positive...
Mark Pegram, MD Though some clinicians may characterize the treatment landscape of HER2-positive...
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved...